Markets:

Overview

News

Currencies

International

Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

13.82 +0.38 (+2.83%)

Streaming Delayed Price Updated: 10:31 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? ↗

April 11, 2024

Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The...

Via Benzinga

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 11, 2024

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Via Benzinga

Topics Stocks

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗

April 11, 2024

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Via Investor's Business Daily

Why Janux Therapeutics Stock Soared as the Market Sagged Today ↗

April 10, 2024

One of the hotter biotech companies on the scene might be changing owners before long.

Via The Motley Fool

Forecasting The Future: 4 Analyst Projections For Janux Therapeutics ↗

March 20, 2024

Via Benzinga

Why Is Infobird (IFBD) Stock Up Today? ↗

February 27, 2024

Infobird stock is up on Tuesday after the SaaS company announced a delay to a planned reverse stock split for shares of IFBD.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst ↗

March 20, 2024

Cantor Fitzgerald's coverage on Janux Therapeutics and its TRACTr/TRACir platform targeting diverse tumor antigens and cancer types. Analysts anticipate substantial growth potential driven by JANX007,...

Via Benzinga

JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 15, 2024

JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

2 Stocks That Have More Than Tripled This Year: Are They Buys? ↗

March 15, 2024

Don't jump on the bandwaggon too quickly.

Via The Motley Fool

B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know ↗

March 13, 2024

Via Benzinga

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 08, 2024

From Janux Therapeutics

Via Business Wire

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 12, 2024

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Via Benzinga

5 Stocks That More Than Doubled In February ↗

March 03, 2024

U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow

Via Talk Markets

Topics Stocks

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? ↗

March 02, 2024

The biotech tantalized investors with a very promising data update.

Via The Motley Fool

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

February 29, 2024

From Janux Therapeutics

Via Business Wire

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares? ↗

February 28, 2024

The company reported in-line sales for the fourth quarter, but shares soared by double digits.

Via Investor's Business Daily

Janux Therapeutics Announces Proposed Public Offering of Common Stock

February 27, 2024

From Janux Therapeutics

Via Business Wire

Stocks Mixed As Consumer Confidence Falls ↗

February 27, 2024

Stocks are mixed midday, after the most recent batch of economic data.

Via Talk Markets

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings ↗

February 27, 2024

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41....

Via Benzinga

Topics Stocks

S&P 500, Nasdaq 100 Dip, Small Caps Surge; Bitcoin Tops $57,000, 2 Biotech Stocks Skyrocket: What's Driving Markets Tuesday? ↗

February 27, 2024

On Tuesday, large-cap indices experienced a downturn, while small caps surged, reflecting investor attention on stock valuations.

Via Benzinga

Topics Stocks

Cancer-Focused Janux Therapeutics Stock Remains Undervalued Despite Price Surge After Study Data: Analyst ↗

February 27, 2024

JANX Therapeutics' updates in cancer treatment: JANX007 shows promising PSA declines in prostate cancer trials, while JANX008 exhibits encouraging clinical activity in solid tumors.

Via Benzinga

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 27, 2024

Via Benzinga

Crude Oil Gains 1%; Macy's Plans To Close 150 Stores ↗

February 27, 2024

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&P...

Via Benzinga

Topics Stocks

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗

February 27, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Via Benzinga

Topics Stocks

Janux Therapeutics Nearly Triples As Prostate Cancer Drug Shows 'Significant Opportunity' ↗

February 27, 2024

The company is working on a treatment for metastatic castration-resistant prostate cancer.

Via Investor's Business Daily

Nasdaq Rises 50 Points; Lowe's Earnings Top Views ↗

February 27, 2024

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose...

Via Benzinga

Topics Stocks

Why Is Aaron’s (AAN) Stock Down 22% Today? ↗

February 27, 2024

Aaron’s stock is taking a beating on Tuesday as AAN investors react to the company's lackluster earnings report for Q4 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 27, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.